Isatuximab plus carfilzomib and dexamethasone in Japanese patients with relapsed multiple myeloma: subgroup analysis of the randomized, open label, phase 3 IKEMA study
Open Access
- 8 September 2022
- journal article
- letter
- Published by Oxford University Press (OUP) in Japanese Journal of Clinical Oncology
- Vol. 52 (12) , 1446-1449
Abstract
No abstract availableFunding Information
- Sanofi
This publication has 13 references indexed in Scilit:
- The Mechanism of Action of the Anti-CD38 Monoclonal Antibody Isatuximab in Multiple MyelomaClinical Cancer Research, 2019
- Management of relapsed and refractory multiple myeloma: novel agents, antibodies, immunotherapies and beyondLeukemia, 2017
- Multiple myelomaNature Reviews Disease Primers, 2017
- Immunotherapies targeting CD38 in Multiple MyelomaOncoImmunology, 2016
- Monoclonal antibodies targeting CD38 in hematological malignancies and beyondImmunological Reviews, 2016
- RETRACTED ARTICLE: SAR650984 directly induces multiple myeloma cell death via lysosomal-associated and apoptotic pathways, which is further enhanced by pomalidomideLeukemia, 2015
- SAR650984, A Novel Humanized CD38-Targeting Antibody, Demonstrates Potent Antitumor Activity in Models of Multiple Myeloma and Other CD38+ Hematologic MalignanciesClinical Cancer Research, 2014
- Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: A multicenter international myeloma working group studyLeukemia, 2011
- Flow Cytometric Immunophenotypic Analysis of 306 Cases of Multiple MyelomaAmerican Journal of Clinical Pathology, 2004
- Flow Cytometric Immunophenotypic Analysis of 306 Cases of Multiple MyelomaAmerican Journal of Clinical Pathology, 2004